Tiansheng Pharmaceutical Group Co., Ltd.

Strengthen physical fitness and enhance immune function

Promote gastrointestinal motility, promote gastric digestive juice secretion, and enhance pepsin activity

Strengthen physical fitness and enhance immune function

Promote gastrointestinal motility, promote gastric digestive juice secretion, and enhance pepsin activity

Promote gastrointestinal motility, promote gastric digestive juice secretion, and enhance pepsin activity

Not yet clear

Not yet clear

Not yet clear

Not yet clear

Not yet clear

It acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis. When used in combination with trimethoprim, it can double block the folic acid metabolism of bacteria and enhance the synergistic antibacterial effect. It has good antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, etc.

It acts on the second step of folic acid anabolism, selectively inhibits the action of dihydrofolate reductase, and when used in combination with sulfamethoxazole, it can double block the folic acid metabolism of bacteria and enhance the synergistic antibacterial effect. It has good antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, etc.

This product belongs to the macrolide antibiotics. It inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome of sensitive bacteria. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), streptococci of all groups and Gram-positive bacilli. Streptococcus pyogenes, group A hemolytic streptococci, Staphylococcus, Streptococcus pneumoniae, meningococci, gonorrhea, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Mycoplasma pneumoniae, Chlamydia, Legionella, Treponema pallidum, Leptospira, and Campylobacter fetus. Non-clinical toxicology studies: In long-term (2-year) studies on rats, oral erythromycin has no evidence of carcinogenicity or gene mutation; studies on male and female rats have shown no reproductive toxicity.

Erythromycin is a macrolide antibiotic with an antibacterial spectrum that includes commonly sensitive strains such as group A Streptococcus, Streptococcus mitis, Streptococcus sanguinis, Pneumococcus, Neisseria meningitidis, Neisseria gonorrhoeae, Bordetella pertussis, Moraxella catarrhalis, Corynebacterium diphtheriae, Listeria monocytogenes, Clostridium difficile, Mycoplasma pneumoniae, Chlamydia trachomatis, Legionella, Treponema pallidum, Leptospira, and Campylobacter; strains with variable sensitivity such as Haemophilus influenzae, Bacteroides fragilis, Clostridium cholerae, and Staphylococcus aureus; and resistant strains such as Enterobacteriaceae and Pseudomonas.